HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $110

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $60 to $110.